RxDoctor Payments Data

Mark Hornfeld, DO

Ophthalmology · New York, NYNPI 1467428573

Payments from drug & device makers

$45,204in general payments, 2019–2025

Across 208 payments — averaging $217.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kaleo, Inc.$41K
  • AbbVie$1K
  • Alcon$421
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$397
  • Johnson & Johnson Surgical Vision, Inc.$326
  • Sun Pharmaceutical Industries Inc.$311
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,8999%
  • Education$490%
  • Other$41,25691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$45,204 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$240,725
Medicare patients
261
Services billed
2,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AlrexLoteprednol Etabonate477$235,329
Brimonidine Tartrate764$113,046
RestasisCyclosporine131$95,400
LumiganBimatoprost160$82,205
ProlensaBromfenac Sodium211$75,413
VyzultaLatanoprostene Bunod142$63,073
Loteprednol Etabonate221$57,717
XdemvyLotilaner30$57,395
Alphagan PBrimonidine Tartrate126$46,825
ZyletTobramycin/Lotepred Etab69$35,564
CombiganBrimonidine Tartrate/Timolol66$31,133
XiidraLifitegrast45$30,334
Bromfenac Sodium141$25,715
Tobramycin-DexamethasoneTobramycin/Dexamethasone542$24,523
RocklatanNetarsudil Mesylat/Latanoprost67$21,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Prolensa, Loteprednol Etabonate, Zylet$397$404,024978 claims
AbbVieRestasis, Lumigan, Alphagan P, Combigan$1,030$255,563483 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$311$109,509209 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$305$57,39530 claims
Eyevance Pharmaceuticals LLCZerviate, Tobradex St, Flarex$144$31,128120 claims
Aerie Pharmaceuticals, Inc.Rocklatan$21$21,48767 claims
AlconSimbrinza$421$13,66466 claims
Sun Pharmaceutical Industries Inc.Bromsite$311$4,26016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →